Drug Profile
Research programme: drug discovery - LineaGen/Amgen
Latest Information Update: 09 Sep 2008
Price :
$50
*
At a glance
- Originator Amgen; LineaGen Research Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 09 Sep 2008 No development reported for Undefined indication in USA (unspecified route)
- 01 Feb 2005 Early research in Undefined in USA (unspecified route)